Posted by Michael Wonder on 16 Nov 2016
Trifluridine-tipiracil combination in colorectal cancer: additional benefit only for some patients
16 November 2016 - Low benefit for patients with K-RAS wild type; survival benefits, but significant side effects and missing quality of life data.
Trifluridine with tipiracil hydrochloride (Lonsurf) has been approved since April 2016 for the treatment of metastatic colorectal cancer. The active substances are suitable for adult patients with metastatic cancer of the intestinal or rectum, in whom the disease progresses despite treatment or for which other therapies are not suitable.
In an early benefit assessment, the Institute for Quality and Efficiency in Health Care has investigated whether the combination concerned has an additional benefit. Accordingly, positive and negative effects are the same certainty of results (evidence). However, the extent of the survival benefit in the two types of tumours differs.
